Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 97,116

Document Document Title
WO/2014/068499A1
This invention relates to a method of increasing a feeling of a) energy or b) cognitive functions, selected from the group consisting of: sustained attention, faster reaction times, and information processing; or c) quality of sleep; or ...  
WO/2014/067505A2
The invention relates to peptides which bind to amino-terminal truncated pEAβ3-42, the free glutamic acid group of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror ima...  
WO/2014/069666A1
An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentrati...  
WO/2014/071194A2  
WO/2014/070745A1
Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.  
WO/2014/069434A1
[Problem] To provide a novel thiazolidinone derivative. [Solution] A thiazolidinone derivative or a pharmaceutically acceptable salt thereof represented by formula (I) or (II). (I) (II)  
WO/2014/068171A1
Compounds of formula I or formula II, wherein Q1Q3 and R1-R5 are as defined in the claims, exhibit CytC derived peroxidase inhibiting activity and are thus useful as CytC derived peroxidase inhibiting agents.  
WO/2014/068327A3
The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.  
WO/2014/071157A1
The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neurona...  
WO/2014/071005A1
Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as a progestogen, such as progesterone or allopreg...  
WO/2014/071282A1
This disclosure relates to methods for improving neural function in a mammal with a proteinopathy comprising administering a therapeutically effective amount of an agent that increases glucocerebrosidase activity in the mammal. Also disc...  
WO/2014/065434A1
The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production,...  
WO/2014/066659A1
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.  
WO/2014/066304A1
Disclosed herein are compounds, compositions, formulations, kits and methods of treatment useful for treating or preventing one or more hyperproliferative disorders, e.g., cancer or a neurological disease or disorder.  
WO/2014/064715A3
The present invention relates to an amorphous form of vilazodone hydrochloride and processes for its preparation. Amorphous vilazodone hydrochloride is prepared by ball milling sieved vilazodone hydrochloride. Further provided are proces...  
WO/2014/064257A1
The invention provides a conjugate comprising(i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonine transporter (SERT) ...  
WO/2014/065194A1
Provided are a nerve growth inhibitor and a cutaneous-sensory-irritation inhibitor, with which cutaneous-sensory irritation and nerve growth based on newly found nerve growth mechanisms can be effectively inhibited. This nerve growth inh...  
WO/2014/064028A1
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of A...  
WO/2014/064131A3
This application discloses compounds according to generic Formula I wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases as...  
WO/2014/063587A1
The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and thei...  
WO/2014/066659A9
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.  
WO/2014/063312A1
The present invention relates to the use of salvianolic acid A in the preparation of drugs for preventing and/or treating cerebral microvascular thromboembolic diseases.  
WO/2014/065270A1
 Provided is a therapeutic agent for neurodegenerative disorders and psychiatric disorders related to mGluR5, the therapeutic agent comprising a compound represented by formula (I) or a pharmaceutically acceptable salt of the same (in ...  
WO/2014/065348A1
A fragment peptide that is composed of a part of HMGB1 protein and has a proper length is synthesized, and it is confirmed that the peptide has a therapeutic effect on spinal cord injury.  
WO/2014/066318A1
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therape...  
WO/2014/065413A1
 A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)  
WO/2014/063199A1
Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in...  
WO/2014/064258A1
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which i...  
WO/2014/064166A1
Mixed inhibitors of aminopeptidase N and of neprilysine are described. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhib...  
WO/2014/065669A1
The invention relates to treatments for cognitive decline and/or memory impairment based on reducing the extracellular matrix in the hippocampus. Improved compositions are provided for such treatments. The invention also relates to detec...  
WO/2014/066132A1
The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease : wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, -OCH3, C1-C3 alkyl,; R3 is H, -...  
WO/2014/065710A1
The invention relates to novel (3-arylsulfonyl-quinoline-8-yl)-dialkyl-amines of general formula 1, or pharmaceutically acceptable salts thereof, which are selective serotonin 5-HT6 receptor antagonists. The compounds can be used as a me...  
WO/2014/065606A1
The present invention provides a composition for preventing and treating nerve disease, comprising osmotin and an inhibitor for inhibiting activity or expression of gamma-aminobutyric acid (GABA) B receptor proteins so as to provide the ...  
WO/2014/066208A1
The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effectiv...  
WO/2014/066695A1
Disclosed is a compound of formula (I). or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions including the compound of formula (I) and methods of using the compound of formula (I).  
WO/2014/066686A1
Provided are method of treatment with MANF. In certain embodiments, the invention provides a method of treating Parkinson's disease by administering MANF to the substantia nigra.  
WO/2014/064038A1
The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula (I) as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are su...  
WO/2014/064162A1
Neprilysin inhibitors are described. The compounds or compositions containing them can be used as antidiarrheal agents, antisecretory agents, anxiolytic agents, antidepressants, cicatrizants, fluid effusion reducers or in the treatment o...  
WO/2014/060941A3
Disclosed are compounds of formula I, their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of...  
WO/2014/060394A1
The present invention relates to ethynyl derivatives of formula (I) or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It ha...  
WO/2014/062548A1
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the ...  
WO/2014/062870A3
A method of treating brain injury or brain trauma in an animal by administering to an animal TSG-6 protein or a biologically active fragment, derivative, or analogue thereof.  
WO/2014/061693A1
The purpose of the present invention is to provide a novel compound that has an ACC2 inhibitory activity. Also provided is a medicinal composition containing the compound. A compound represented by formula (I) or a pharmaceutically accep...  
WO/2014/060509A1
The use of a bioactivated phytochemical is disclosed for preventing and treating neurodegenerative diseases, such as Parkinson's disease and multiple sclerosis. In particular, said bioactivated phytochemical is Rs-Glucoraphanin bioactiva...  
WO/2014/063071A1
Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50 200 IU, preferably 120 170 IU, more preferably 140 160 I...  
WO/2014/063057A1
The present invention provides a method for treating, alleviating, reversing or delaying progression of at least one symptom of Parkinson's Disease in a subject in need thereof by administering to the subject an effective amount of a 2-a...  
WO/2014/060386A1
The present invention provides compounds of formula (I), wherein Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture ...  
WO/2014/060384A1
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optic...  
WO/2014/060112A1
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...  
WO/2014/060398A1
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro R2 is hydrogen or methyl or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its correspondin...  

Matches 551 - 600 out of 97,116